Left out thus far in the cannabis-related bonanza that has gripped markets over the past 6 weeks is GB Sciences Inc (OTCMKTS:GBLX). The stock is often a late bloomer, but a potentially big bloomer when it starts running. At this point, the stock is starting to spark to life a bit, helped by its recent announcement that it has been granted a recreational production license for the manufacture of cannabis oils.
According to the release, “Oils are the base ingredient for vape products, tinctures, edibles, and nutraceutical formulations. The Company received its medical marijuana production license on February 2, 2018. The State of Nevada instructed them to apply for the recreational license in June, for upgraded licenses. The Company’s anticipated revenues from extracted and infused products were delayed by six months. Now, with the issuance of the recreational oil production license, the Company can begin selling its tinctures, oils, vape pens and edibles with estimated revenue starting at around $100,000 per month and growing to at least $300,000 per month.”
GB Sciences Inc (OTCMKTS:GBLX) as a company that seeks to be an innovative technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for a variety of ailments.
The Company is developing and utilizing state of the art technologies in plant biology, cultivation and extraction techniques, combined with biotechnology, and plans to produce consistent and measurable medical-grade cannabis, cannabis concentrates and cannabinoid therapies.
“Although we believe that maximum shareholder value will ultimately be achieved through the development, production, and marketing of certified cannabinoid medicines, therapies and treatments, in order to generate cash flow and near-term profitability, we intend to cultivate and dispense cannabis for medical purposes in both Nevada and other states which permit such sales and in which we and our operating partners are able to obtain cultivation and dispensing licenses. We seek to become a trusted producer of consistent and efficacious medicinal strains and products, combining both cannabinoids and terpenes, which we intend to market in those states within the United States and in other countries where the sale of medical cannabis products are permitted. In addition, subject to obtaining Food and Drug Administrative (FDA) certification, we intend to market our cannabinoid-based drug discoveries on a worldwide basis.”
GBLX claims to produce measurable medical-grade cannabis, cannabis concentrates, and cannabinoid therapies through using various technologies in plant biology, cultivation, and extraction techniques combined with biotechnology.
It also claims to be involved in the development of controlled-climate indoor agricultural technology growing and cultivation suites, including TissueBLOX, GrowBLOX, CureBLOX, and ExtractionLAB.
According to additional company materials, “GB Sciences, Inc. (GBLX) is a diverse cannabis company, focused on cultivation as well as biopharmaceutical research and development. The Company’s goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions.”
Find out when $GBLX stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
“We have spent a lot of time, care and effort in selecting and cultivating the best genetics for their natural abilities to deal with specific disease conditions. Now whole plant extraction without using solvents allow us to complete the delivery on our promise… pure, consistent, and trusted raw ingredients in everything we do. We have planned on this opportunity for a long time. And now that it’s here, we can’t wait to get started.”
We’ve witnessed 35% during the past week in terms of shareholder gains in the listing, but that move comes in the context of a larger bearish trend. In addition, the name has witnessed a pop in interest, as transaction volume levels have recently pushed 120% beyond what we have been seeing over the larger time frame.
CEO and Chairman of the Board, John Poss, states, “This is a great opportunity to spread our core scientific approach to multiple new retail products. Our core tenets of purity, consistency and trust can now truly extend from seed to sale across multiple lines of cannabis products. It is the first step in building and introducing a national, trusted brand family. This is a true inflection point in the growth of GB Sciences.”
Now commanding a market cap of $82.76M, GBLX has a significant war chest ($4.7M) of cash on the books, which compares with about $2M in total current liabilities. One should also note that debt has been growing over recent quarters. GBLX is pulling in trailing 12-month revenues of $3.6M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 2331.3%. This may be a very interesting story and we will look forward to updating it again soon. Sign-up for continuing coverage on shares of $GBLX stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $GBLX, either long or short, and we have not been compensated for this article.